Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 15/20 | 0.52 |
| ▸ | DRD3 | P35462 | 13/20 | 0.52 |
| ▸ | DRD4 | P21917 | 9/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.45 |
| ▸ | HTR1A | P08908 | 2/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3439799 | 0.97 | DRD2 (0.48) | DRD2DRD3DRD4OPRM1KMT2A | |
| SCHEMBL13063127 | 0.91 | DRD2 (0.48) | DRD2DRD3DRD4OPRM1HTR1A | |
| SCHEMBL13063379 | 0.89 | DRD2 (0.48) | DRD2DRD3DRD4OPRM1HTR1A | |
| SCHEMBL13063129 | 0.88 | DRD2 (0.52) | DRD2DRD3DRD4OPRM1HTR1A | |
| SCHEMBL12047501 | 0.81 | DRD2 (0.46) | DRD2DRD3 | |
| SCHEMBL3439732 | 0.80 | DRD2 (0.52) | DRD2DRD3DRD4OPRM1HTR1A | |
| SCHEMBL3439811 | 0.79 | DRD2 (0.43) | DRD2DRD3DRD4HTR1AMEN1 | |
| SCHEMBL3439982 | 0.77 | DRD2 (0.48) | DRD2DRD3DRD4OPRM1HTR1A | |
| SCHEMBL12012107 | 0.77 | MAPT (0.52) | MEN1KMT2A | |
| SCHEMBL12914429 | 0.76 | DRD2 (0.46) | DRD2DRD3DRD4OPRM1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7858618-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-28 | — | — | US | disclosed |
| US-20090137545-A1 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137545-A1 | Compounds | ADORA2B, ABCB11, CYP11B1 | DRD2 45/4885DRD3 33/4885DRD4 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.